# Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

> **NCT00021034** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** chemotherapy
- **DRUG:** taurolidine

## Key facts

- **NCT ID:** NCT00021034
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** 2001-08
- **Final completion:** 2001-08
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00021034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00021034, "Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00021034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*